12,602 Shares in Bristol Myers Squibb Company $BMY Purchased by Axim Planning & Wealth

Axim Planning & Wealth purchased a new position in Bristol Myers Squibb Company (NYSE:BMY) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 12,602 shares of the biopharmaceutical company’s stock, valued at approximately $680,000. Bristol Myers Squibb makes up about 0.7% of Axim Planning & Wealth’s holdings, making the stock its 21st largest position.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Arrowstreet Capital Limited Partnership grew its holdings in Bristol Myers Squibb by 15.9% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 17,190,560 shares of the biopharmaceutical company’s stock worth $927,259,000 after purchasing an additional 2,356,583 shares during the period. Atlas Capital Advisors Inc. purchased a new stake in Bristol Myers Squibb in the fourth quarter worth about $263,000. Aptus Capital Advisors LLC grew its holdings in Bristol Myers Squibb by 7.2% in the fourth quarter. Aptus Capital Advisors LLC now owns 65,893 shares of the biopharmaceutical company’s stock worth $3,554,000 after purchasing an additional 4,419 shares during the period. Apriem Advisors grew its holdings in Bristol Myers Squibb by 3.8% in the fourth quarter. Apriem Advisors now owns 11,642 shares of the biopharmaceutical company’s stock worth $628,000 after purchasing an additional 430 shares during the period. Finally, Kestra Advisory Services LLC grew its holdings in Bristol Myers Squibb by 0.8% in the fourth quarter. Kestra Advisory Services LLC now owns 196,317 shares of the biopharmaceutical company’s stock worth $10,589,000 after purchasing an additional 1,484 shares during the period. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BMY. Guggenheim restated a “buy” rating and issued a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Citigroup restated a “neutral” rating on shares of Bristol Myers Squibb in a report on Friday, May 1st. Cantor Fitzgerald increased their price target on shares of Bristol Myers Squibb from $45.00 to $54.00 and gave the company a “neutral” rating in a report on Wednesday, April 8th. Weiss Ratings reiterated a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday, March 23rd. Finally, Piper Sandler reiterated an “overweight” rating and set a $75.00 price target (up from $66.00) on shares of Bristol Myers Squibb in a report on Monday, February 23rd. Eight equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $61.31.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 30,000 shares of the stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $61.67, for a total value of $1,850,100.00. Following the transaction, the executive vice president directly owned 159,248 shares in the company, valued at approximately $9,820,824.16. This trade represents a 15.85% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.05% of the company’s stock.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Analyst commentary highlighted that BMY’s growth portfolio now generates more than half of revenue, with Reblozyl, Breyanzi and Cobenfy delivering strong gains that help balance declines in legacy products. Article Title
• Positive Sentiment: Bristol Myers Squibb advanced its Phase 1 liver study for BMS-986435, adding another pipeline update that supports long-term growth prospects. Article Title
• Positive Sentiment: The company also reported momentum in its mavacamten heart-drug franchise, with a real-world study signaling continued traction in the cardiovascular market. Article Title
• Neutral Sentiment: Bristol Myers is rolling out an AI-driven procurement overhaul and expanding an oncology collaboration with Arcus Biosciences, which could improve efficiency and bolster its cancer pipeline over time. Article Title
• Neutral Sentiment: Erste Group made only small tweaks to earnings estimates, leaving FY2026 in line with consensus and slightly trimming FY2027, a mixed signal that does not materially change the near-term outlook. Article Title
• Negative Sentiment: Takeda said its AI-designed psoriasis pill beat Bristol Myers’ Sotyktu in a head-to-head trial, raising competitive concerns for one of BMY’s dermatology assets. Article Title

Bristol Myers Squibb Stock Up 0.3%

BMY opened at $57.05 on Friday. The company has a current ratio of 1.42, a quick ratio of 1.28 and a debt-to-equity ratio of 2.10. Bristol Myers Squibb Company has a 1-year low of $42.52 and a 1-year high of $62.89. The company has a market capitalization of $116.49 billion, a PE ratio of 16.02, a PEG ratio of 0.16 and a beta of 0.24. The firm’s 50 day simple moving average is $57.73 and its two-hundred day simple moving average is $56.87.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The business had revenue of $11.49 billion for the quarter, compared to the consensus estimate of $10.93 billion. During the same period last year, the firm earned $1.80 earnings per share. The company’s quarterly revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts forecast that Bristol Myers Squibb Company will post 6.32 EPS for the current year.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.